Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.
The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.
The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.
The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.